Skip to main content
Erschienen in: Current Atherosclerosis Reports 2/2013

01.02.2013 | Statin Drugs (MB Clearfield, Section Editor)

Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?

verfasst von: Karlyn Huddy, Pavittarpaul Dhesi, Paul D. Thompson

Erschienen in: Current Atherosclerosis Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Statins are widely used for their cholesterol-lowering properties and proven reduction of cardiovascular disease risk. Many patients take statins as long-term treatment for a variety of conditions without a clear-cut understanding of how treatment duration affects the frequency of adverse effects. We aimed to evaluate whether the frequencies of documented adverse events increase, decrease, or remain unchanged with long-term statin use. We reviewed the established literature to define the currently known adverse effects of statin therapy, including myopathy, central nervous system effects, and the appearance of diabetes, and the frequency of these events with long-term medication use. The frequency of adverse effects associated with long-term statin therapy appears to be low. Many patients who develop side effects from statin therapy do so relatively soon after initiation of therapy, so the frequency of side effects from statin therapy when expressed as a percentage of current users decreases over time. Nevertheless, patients may develop side effects such as muscle pain and weakness years after starting statin therapy; however, the absolute number of patients affected by statin myopathy increases with treatment duration. Also, clinical trials of statin therapy rarely exceed 5 years, so it is impossible to determine with certainty the frequency of long-term side effects with these drugs.
Literatur
1.
2.
Zurück zum Zitat •• Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(1):875–81. This review of the literature evaluates data on statin safety with to regard to cognition, cancer, and new-onset diabetes.PubMedCrossRef •• Jukema JW, Cannon CP, de Craen AJM, Westendorp RGJ, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(1):875–81. This review of the literature evaluates data on statin safety with to regard to cognition, cancer, and new-onset diabetes.PubMedCrossRef
3.
4.
Zurück zum Zitat Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72.PubMedCrossRef Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40(3):567–72.PubMedCrossRef
5.
Zurück zum Zitat Bays H. Statin safety: an overview and assessment of the data–2005. Am J Cardiol. 2006;97(8A):6C–26C.PubMedCrossRef Bays H. Statin safety: an overview and assessment of the data–2005. Am J Cardiol. 2006;97(8A):6C–26C.PubMedCrossRef
6.
Zurück zum Zitat Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6.PubMedCrossRef Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med. 2005;165(22):2671–6.PubMedCrossRef
7.
Zurück zum Zitat Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–53.PubMedCrossRef Cham S, Evans MA, Denenberg JO, Golomb BA. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30(6):541–53.PubMedCrossRef
8.
Zurück zum Zitat Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One. 2008;3(6):e2522.PubMedCrossRef Molokhia M, McKeigue P, Curcin V, Majeed A. Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991–2006. PLoS One. 2008;3(6):e2522.PubMedCrossRef
9.
Zurück zum Zitat Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med. 2011;50(8):845–53.PubMedCrossRef Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med. 2011;50(8):845–53.PubMedCrossRef
10.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRef Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto Jr AM, JUPITER Study Group, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.PubMedCrossRef
11.
Zurück zum Zitat de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, et al. Phase Z of the A to Z trial. JAMA. 2004;292(11):1307–16.PubMedCrossRef de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KAA, et al. Phase Z of the A to Z trial. JAMA. 2004;292(11):1307–16.PubMedCrossRef
12.
Zurück zum Zitat Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation. 2002;105(20):2341–6.PubMedCrossRef Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation. 2002;105(20):2341–6.PubMedCrossRef
13.
Zurück zum Zitat Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26–35.PubMedCrossRef Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther. 2006;28(1):26–35.PubMedCrossRef
14.
Zurück zum Zitat Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–97.PubMedCrossRef Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114(25):2788–97.PubMedCrossRef
15.
Zurück zum Zitat Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.CrossRef
16.
Zurück zum Zitat Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549–57.PubMedCrossRef Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549–57.PubMedCrossRef
17.
Zurück zum Zitat Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871–80.PubMedCrossRef Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23(7):871–80.PubMedCrossRef
18.
Zurück zum Zitat Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627–31.PubMedCrossRef Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627–31.PubMedCrossRef
19.
Zurück zum Zitat Hajjar J, Schumpert J, Hirth V, Wieland D, Eleazor GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol. 2002;57A(7):M414–8. Hajjar J, Schumpert J, Hirth V, Wieland D, Eleazor GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol. 2002;57A(7):M414–8.
20.
Zurück zum Zitat Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atrovastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4):259–65.PubMedCrossRef Parale GP, Baheti NN, Kulkarni PM, Panchal NV. Effects of atrovastatin on higher functions. Eur J Clin Pharmacol. 2006;62(4):259–65.PubMedCrossRef
21.
Zurück zum Zitat Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoggerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250–1.PubMedCrossRef Berk-Planken I, de Konig I, Stolk R, Jansen H, Hoggerbrugge N. Atorvastatin, diabetic dyslipidemia, and cognitive functioning. Diabetes Care. 2002;25(7):1250–1.PubMedCrossRef
22.
Zurück zum Zitat Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55(3):420–5.PubMedCrossRef Agostini JV, Tinetti ME, Han L, McAvay G, Foody JM, et al. Effects of statin use on muscle strength, cognition, and depressive symptoms in older adults. J Am Geriatr Soc. 2007;55(3):420–5.PubMedCrossRef
23.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, PROSPER study group, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.PubMedCrossRef Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, PROSPER study group, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.PubMedCrossRef
24.
Zurück zum Zitat Hyttinen L, TuulioHenriksson A, Vuorio AF, Kuosmanen N, Harkanen T, et al. Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls. J Alzheimers Dis. 2010;21(2):611–7.PubMed Hyttinen L, TuulioHenriksson A, Vuorio AF, Kuosmanen N, Harkanen T, et al. Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls. J Alzheimers Dis. 2010;21(2):611–7.PubMed
25.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.PubMedCrossRef Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.PubMedCrossRef
26.
Zurück zum Zitat Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRef Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.PubMedCrossRef
27.
Zurück zum Zitat Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24(5):1359–62.PubMedCrossRef Coleman CI, Reinhart K, Kluger J, White CM. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2008;24(5):1359–62.PubMedCrossRef
Metadaten
Titel
Do the Frequencies of Adverse Events Increase, Decrease, or Stay the Same with Long-Term Use of Statins?
verfasst von
Karlyn Huddy
Pavittarpaul Dhesi
Paul D. Thompson
Publikationsdatum
01.02.2013
Verlag
Current Science Inc.
Erschienen in
Current Atherosclerosis Reports / Ausgabe 2/2013
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-012-0301-9

Weitere Artikel der Ausgabe 2/2013

Current Atherosclerosis Reports 2/2013 Zur Ausgabe

Statin Drugs (MB Clearfield, Section Editor)

Statins and Diabetes: The Good, the Bad, and the Unknown

Statin Drugs (MB Clearfield, Section Editor)

Does the Benefit from Statin Therapy Extend Beyond 5 Years?

Nonstatin Drugs (WB Borden, Section Editor)

Pharmacologic Interactions of Multidrug Therapy for Dyslipidemia

Nonstatin Drugs (WB Borden, Section Editor)

Advances in Pharmacologic Therapies for Type 2 Diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.